TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06693856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-Dose Methylprednisolone
Description: Methylprednisolone is administered at a dose of 1mg/kg, given as an intravenous injection once daily for 3 consecutive days, repeated every 4 weeks for a total of 24 weeks, followed by a follow-up period.
Study: NCT06640400

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiovascular ultrasound
Description: Participants in the intervention group will be treated with a medical LIPUS device (838C-M-L-I/II, Shenzhen, China) for 10 days in addition to conventional medical treatment. The ultrasound therapy instrument is equipped with a sound head comprising 5 transducer units, operating at an ultrasonic frequency of 0.84MHz with a sound intensity range of 1 W/cm2 -1.25 W/cm2. The therapeutic ultrasound sessions necessitate a controlled environmental temperature. Patients will assume the supine position, exposing the precordial region, with the five-pronged head positioned parallel to the heart\&amp;amp;amp;amp;#39;s long axis, covering the entire precordial region including the right and left coronary arterial trunks and the aortic root. The ultrasound therapy device operates in a pulsed mode, with each treatment session lasting 20 minutes, comprising 2 daily sessions for a total of 20 treatments.
Study: NCT05445804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 300 mg Cannabidiol
Description: 300 mg CBD in Medium Chain Triglyceride oil b.i.d.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 300 mg Cannabidiol
Description: 300 mg CBD in Medium Chain Triglyceride oil b.i.d.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 600 mg Cannabidiol
Description: 600 mg CBD in Medium Chain Triglyceride oil b.i.d.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 600 mg Cannabidiol
Description: 600 mg CBD in Medium Chain Triglyceride oil b.i.d.
Study: NCT05062317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FLUOROURACIL
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given by PO
Study: NCT05445804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Medium Chain Triglyceride oil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Medium Chain Triglyceride oil
Study: NCT06539897

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sexual education
Description: These sessions of the sexual education program aim to increase women's knowledge and awareness about their own bodies. Women are informed about their own bodies, their identities, and the stages of sexual response, aiming to make the process clearer and more understandable. They will be encouraged to discover what sexuality means to them, their knowledge about sexuality will be questioned, and sexual myths, if any, will be revealed, and correct information about sexual myths will be provided to normalize sexuality. In addition, discussions will be held on the meanings of being a woman and an older woman, and women's perspectives on themselves and their self-esteem will be emphasized. In the third session, participants will be taught effective communication techniques to improve their communication skills with their partners.
Study: NCT05946239

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manage My Pain App
Description: This digital application helps patients measure, track, and manage chronic pain, functionality, and medication use. MMP can also be used to share patient pain experiences with their circle of care via reports and offers educational resources for patients.
Study: NCT05887661

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hypovolemic phlebotomy
Description: hypovolemic phlebotomy was performed after induction of anesthesia and before the star of parenchymal division, with a goal-directed low central venous pressure drop to 5mmHg.
Study: NCT05062317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Given by IV
Study: NCT00053339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab
Study: NCT05062317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given by IV
Study: NCT04292717

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Gait training
Description: All participants will receive training three times a week for 6 weeks (18 training sessions) at the University Hospital Balgrist, Spinal Cord Injury Centre. Each exercise session will last for 1 hour and will be conducted and supervised by an experienced physical therapist.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Gait training
Description: All participants will receive training three times a week for 6 weeks (18 training sessions) at the University Hospital Balgrist, Spinal Cord Injury Centre. Each exercise session will last for 1 hour and will be conducted and supervised by an experienced physical therapist.
Study: NCT04752657

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Delayed administration of survey modules
Description: The intervention consists in delaying the administration of the physical function, physical activity, and events survey modules by 2 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Regular administration of survey modules
Description: The physical function, physical activity, and events survey modules are administered according to the regular pattern
Study: NCT05184764

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AP-SA02
Description: Bacteriophage administered via intravenous bolus infusion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive Placebo administered via intravenous bolus infusion
Study: NCT05101213

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Virus-specific Cytotoxic T-lymphocytes
Description: Given IV
Study: NCT05222906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venglustat
Description: tablet; oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: imiglucerase
Description: sterile lyophilized product; intravenous
Study: NCT06099717

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dual-cantilevered implant bridge
Description: A 3-unit supported by one implant in the middle

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 3-unit iFDP
Description: 3-unit fixed dental prosthesis supported by two implants
Study: NCT06411899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sonelokimab
Description: Sonelokimab

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05604612

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Corticision
Description: Incisions in the cortical plate of maxillary bone
Study: NCT04904146

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood tests and testing of analysis of the lymphoma microenvironment in skin, skin barrier and skin microbiology profile.
Description: The study aims to perform systematic translational sampling of each patient from study start until end-of-study, or at longest for a three year period for each patient. Treatment will be performed according to clinical routine.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood tests and testing of analysis of the lymphoma microenvironment in skin, skin barrier and skin microbiology profile.
Description: The study aims to perform systematic translational sampling of each patient from study start until end-of-study, or at longest for a three year period for each patient. Treatment will be performed according to clinical routine.
Study: NCT05667428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leuprorelin
Description: From the initial chemotherapy after diagnosis, patients received a subcutaneous injection of leprorelin in each cycle of chemotherapy including the conditioning treatment prior to transplantation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: From the initial chemotherapy after diagnosis, patients received a subcutaneous injection of normal saline in each cycle of chemotherapy including the conditioning treatment prior to transplantation.
Study: NCT06415578

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ergonomics training
Description: In this training; What is ergonomics, the importance of ergonomics, the purpose of ergonomics, risk factors for musculoskeletal disorders that can be seen in e-sports players, ergonomic arrangements that can be made in the working environment and methods of protection from musculoskeletal injuries, posture disorders and various ergonomic arrangements that can be made for posture disorders and chair selection, screen selection. selection and rest breaks were included. Participants will be trained twice in total, on the first day of the study and at the end of the 4th week. The training will be carried out interactively, supported by videos and visuals. Training will be done individually and will last approximately 2 hours.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ergonomics training
Description: In this training; What is ergonomics, the importance of ergonomics, the purpose of ergonomics, risk factors for musculoskeletal disorders that can be seen in e-sports players, ergonomic arrangements that can be made in the working environment and methods of protection from musculoskeletal injuries, posture disorders and various ergonomic arrangements that can be made for posture disorders and chair selection, screen selection. selection and rest breaks were included. Participants will be trained twice in total, on the first day of the study and at the end of the 4th week. The training will be carried out interactively, supported by videos and visuals. Training will be done individually and will last approximately 2 hours.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercises
Description: The exercise training program will be implemented for 8 weeks, 3 days a week, lasting an average of 45 minutes. All participants will be given information about the exercises before the exercise training. The exercise protocol was designed as 3 parts: warm-up, exercise and cool-down. Stretching exercises, mobility and strength exercises will be applied. A rest period of 30-45 seconds was given between sets and 2-3 minutes between exercises. Participants will be given dynamic and static stretching, nerve stretching, postural strength and functional exercises for the upper extremity. Relevant movements will be modified according to the exercise capacity of the participants. Exercise content will also include median, ulnar and radial nerve stretching, neck and thoracic mobility exercises, and functional strength exercises for the shoulder, arm, hand and wrist. Exercise tracking will be checked regularly through online conversations.
Study: NCT06243757

Intervention type: OTHER
Intervention: MDASI-GI
Description: The MDASI-GI assesses 5 symptoms specific to gastrointestinal cancer:~constipation diarrhea or watery stools difficulty swallowing change in taste feeling bloated~Using this questionnaire, participants score the severity of their symptoms over the previous 24 hours on a scale of 0 (not present) to 10 (as bad as you can imagine).

Intervention type: OTHER
Intervention: MDASI-GI
Description: The MDASI-GI assesses 5 symptoms specific to gastrointestinal cancer:~constipation diarrhea or watery stools difficulty swallowing change in taste feeling bloated~Using this questionnaire, participants score the severity of their symptoms over the previous 24 hours on a scale of 0 (not present) to 10 (as bad as you can imagine).
Study: NCT06177834

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alisklamp
Description: Alisklamp

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dorsal slit circumcision technique
Description: In this group, included the patients who will operated with dorsal slit circumcision technique
Study: NCT05684159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NM8074
Description: NM8074 will be administered as an intravenous infusion. In Cohort 1, all subjects will be administered 20 mg/kg of NM8074 intravenously every two weeks for a total of 7 doses from Day 1 to Day 85 of the Treatment Period. Patients in Cohort 2 will receive weekly doses of 10 mg/kg for a total of 4 doses from Day 1 to Day 22 followed by biweekly doses at 20 mg/kg for a total of 5 doses from Day 29 to Day 85.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NM8074
Description: NM8074 will be administered as an intravenous infusion. In Cohort 1, all subjects will be administered 20 mg/kg of NM8074 intravenously every two weeks for a total of 7 doses from Day 1 to Day 85 of the Treatment Period. Patients in Cohort 2 will receive weekly doses of 10 mg/kg for a total of 4 doses from Day 1 to Day 22 followed by biweekly doses at 20 mg/kg for a total of 5 doses from Day 29 to Day 85.
Study: NCT06442709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab Asprin
Description: Tocilizumab alone, Asprin alone, Tocilizumab combined with Asprin. Tocilizumab, an IL6R inhibitor, injected once a month at a dose of 4mg/kg in advanced NPC patients.~Asprin，an anticoagulant, taken orally once daily at a dose of 100mg in advanced NPC patients.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo replaces tocilizumab and asprin in advanced NPC patients.
Study: NCT06192589

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabidiol
Description: Cannabidiol (Epidiolex) will be administered orally 2.5 mg/kg twice daily (5 mg/kg/day) for 28 days in Part 1 and for 9 days (morphine cohort) or 12 days (citalopram cohort) in Part 2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabidiol
Description: Cannabidiol (Epidiolex) will be administered orally 2.5 mg/kg twice daily (5 mg/kg/day) for 28 days in Part 1 and for 9 days (morphine cohort) or 12 days (citalopram cohort) in Part 2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabidiol
Description: Cannabidiol (Epidiolex) will be administered orally 2.5 mg/kg twice daily (5 mg/kg/day) for 28 days in Part 1 and for 9 days (morphine cohort) or 12 days (citalopram cohort) in Part 2.
Study: NCT06169748

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real UHCDS a-tDCS
Description: Real UHCDS a-tDCS (STARTSTIM® 8 stimulator, Neuroelectric Barcelona, Spain) for ten sessions (three sessions per week in weeks 1 and 2; and one session per week in weeks 3, 4, 5 and 6). UHCDS a-tDCS is a galvanic current applied by a cap for 20 minutes at an intensity of 2 milliamps.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham UHCDS a-tDCS
Description: Sham UHCDS a-tDCS (STARSTIM® 8 stimulator, Neuroelectric Barcelona, Spain) for ten sessions (three sessions per week in weeks 1 and 2; and one session per week in weeks 3, 4, 5 and 6). Sham tDCS will be applied for the same time than real UHCDS a-tDCS.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapeutic exercise
Description: The therapeutic exercise program will include aerobic exercise and muscle strengthening in the same days as UHCDS a-tDCS. The program will last 30-45 minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Therapeutic exercise
Description: The therapeutic exercise program will include aerobic exercise and muscle strengthening in the same days as UHCDS a-tDCS. The program will last 30-45 minutes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic exercise
Description: The therapeutic exercise program will include aerobic exercise and muscle strengthening in the same days as UHCDS a-tDCS. The program will last 30-45 minutes.
Study: NCT06236009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-004
Description: TAK-004 subcutaneous injections.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-004
Description: TAK-004 subcutaneous injections.
Study: NCT05967351

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: delandistrogene moxeparvovec
Description: No study drug will be administered as part of this study. Eligible participants who received treatment with delandistrogene moxeparvovec during a previous clinical study will be included.
Study: NCT04501328

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CIC+VA-CRAFT
Description: CIC+VA-CRAFT consists of four 45-min. telephone coaching calls over 8-12 weeks, delivered by a coach following a manual, while participants are completing the VA-CRAFT for PTSD web-based course.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CIC
Description: Coaching Into Care is an existing national VA program that provides telephone consultation and coaching to family members of Veterans with mental health needs who want to help connect them with mental health care by providing referrals, educational information, and a unique coaching service to help callers talk to their Veterans about their decision to seek care.
Study: NCT04632966

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological: PTP-001
Description: allogeneic placental tissue particulate

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological: PTP-001
Description: allogeneic placental tissue particulate
Study: NCT05956717

Intervention type: DEVICE
Intervention: Orthokeratology
Description: The experimental group wore orthokeratology lenses
Study: NCT05822726

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Prostate biopsy
Description: Targeted guided puncture biopsy guided by B-ultrasound will be performed (in addition to 12-needle system biopsy, if PSMA-PET/MRI or mpMRI indicates a positive lesion, puncture biopsy should be added at the lesion displayed on image, the 12-needle system biopsy+X scheme).

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Prostate biopsy
Description: Targeted guided puncture biopsy guided by B-ultrasound will be performed (in addition to 12-needle system biopsy, if PSMA-PET/MRI or mpMRI indicates a positive lesion, puncture biopsy should be added at the lesion displayed on image, the 12-needle system biopsy+X scheme).
Study: NCT06283888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYP2C19 Genotype Guided DAPT
Description: Patients with \*2 or \*3 carrier will be received ticagrelor 60mg or 45mg bid (if \<50 kg, ≥75 years) + aspirin 100 mg qd; Patients with \*2 or \*3 non-carrier will be received clopidogrel 75mg qd + aspirin 100 mg qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conventional DAPT
Description: Patients will be conventionally received ticagrelor 90mg bid or clopidogrel 75mg qd + aspirin 100 mg qd
Study: NCT06561581

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Acuity
Description: Enhancement to Motivity product for clinical decision support

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acuity
Description: Enhancement to Motivity product for clinical decision support
Study: NCT04759989

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Actual Body Weight Dosing
Description: 30cc/kg initial bolus calculated using Actual Body Weight

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adjusted Body Weight Dosing
Description: 30cc/kg initial bolus calculated using Adjusted Body Weight

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ideal Body Weight Dosing
Description: 30cc/kg initial bolus calculated using Ideal Body Weight
Study: NCT05699538

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Minimal-Dose Home-Based Resistance Exercise
Description: 8-week home-based resistance exercise performed one day per week.
Study: NCT05251805

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood, bone marrow and lung tumor tissue collection
Description: Blood sampling: 12ml of blood will be collected during the routine pre-operative blood collection~Bone marrow aspiration during thoracic surgery: following the surgical intervention, bone marrow aspiration will be performed through the incisions made for the thoracic procedure. The ribs lying directly above and below the trocar incision will be exposed. A bone marrow needle will be advanced into the periost until the needle tip reaches the bone marrow. After removing the stylet a 2ml syringe will be attached to the aspiration needle and 0.5ml to 2ml of bone marrow will be aspirated before removing the needle. This procedure will be repeated twice for every trocar site, for a maximum of 3 trocar sites, or until 5ml of bone marrow aspirate is obtained.~Lung tumor collection: all surgical samples will be analyzed by our anatomopathological department. Viable and fresh material, not used for the diagnostic purposes, will be sent to the LMCT.
Study: NCT05945472

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Positive reinforcement method
Description: A 30-minute talk based on mindfulness, positive thinking and teaching for the application of the cosmetic through positive messages (Ayuna method). Adapts the teachings of mindfulness to the field of beauty and stimulates the skin-brain connection through self-care. By applying cosmetics through intentional massages, with this technique is stimulated the brain in a positive positively in the general wellbeing.~The cosmetic is applied with a massage aimed at loving oneself, a ceremony for the skin and an invitation to enjoy the moment; positive messages are included during the application. In addition to favoring the penetration of the products, these maneuvers help to disconnect and achieve, in the long term, a healthier appearance. The technique consists of slow, intentional movements to create an ideal space to become aware of the present moment and draw a love story with oneself.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard method
Description: A 30-minute talk based on how to administer it according to the guidelines of general cosmetology, related to the use and application of the cream, following conventional techniques of the cosmetic industry, which focus on the application of the product in the areas of wrinkles or with more treatment needs: anti-aging anti-stain anti-sagging anti-sagging product, anti-sagging anti-sagging anti-sagging anti-sagging anti-sagging anti-sagging product. rejuvenating results to try to reduce the skin years, reduce wrinkles, loss of firmness, flaccidity and spots.